Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 38 Researches
7.3
USERS' SCORE
Good
Based on 19 Reviews
8.3
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%**
Saturated Fat
< 0.5 g
2%**
Polyunsaturated Fat
0.5 g
†
Fish Oil Concentrate
1 g (1,000 mg)
†
Omega-3 Fatty Acids:
Eicosapentaenoic Acid (EPA)
180 mg
†
Docosahexaenoic Acid (DHA)
120 mg
†
Top Medical Research Studies
9
We examined the relationship between plasma omega-3 levels and heart failure (HF), focusing on how this affects mortality in patients with existing HF. Our analysis of the UK Biobank, which included nearly 272,000 participants without HF, showed that higher omega-3 levels were linked to a 21% lower risk of developing HF over nearly 14 years.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
Read More
8
We investigated how eicosapentaenoic acid (EPA) affects heart rhythm, particularly in the context of high-fat diets. In our study, mice were divided into two groups: one received a high-fat diet, while the other’s diet was supplemented with EPA for eight weeks.
We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
Read More
9
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Read More
Most Useful Reviews
7.5
Improves heart rhythm
1 people found this helpful
These capsules are huge, which was surprising, but the taste is minimal. Since taking them, I've felt a marked improvement in my heart condition and rhythm.
Read More
9
No fishy taste
I appreciate the good price and concentration of this product. It’s halal and odourless, making it easy to consume, and it's effective for heart health.
Read More
9
Promotes heart health
NOW Foods Omega-3 provides 1000 mg per softgel with targeted EPA and DHA doses. It has an enteric coating that removes any fishy aftertaste, making it excellent for heart health and cognitive function.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 38 Researches
7.3
- All Researches
9
We analyzed the impact of different fatty acid-derived acylcarnitines on heart health. The study found that saturated and monounsaturated acylcarnitines, especially trans-elaidoylcarnitine, significantly impaired heart function and mitochondrial activity, leading to cardiotoxicity.
In contrast, omega-3-derived acylcarnitines, like eicosapentaenoylcarnitine and docosahexaenoylcarnitine, were found to be safe, having little to no negative effect on heart function and cell viability. Overall, this research suggests that omega-3 fatty acids may be a safer option for those facing cardiac challenges.
In contrast, omega-3-derived acylcarnitines, like eicosapentaenoylcarnitine and docosahexaenoylcarnitine, were found to be safe, having little to no negative effect on heart function and cell viability. Overall, this research suggests that omega-3 fatty acids may be a safer option for those facing cardiac challenges.
Read More
9
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Read More
9
We examined the relationship between plasma omega-3 levels and heart failure (HF), focusing on how this affects mortality in patients with existing HF. Our analysis of the UK Biobank, which included nearly 272,000 participants without HF, showed that higher omega-3 levels were linked to a 21% lower risk of developing HF over nearly 14 years.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
Read More
9
Omega-3 benefits African Americans’ heart health
We observed that the role of omega-3 fatty acids in heart health showed promising results specifically for African Americans. By comparing matched groups from the VITAL trial, we found that omega-3 supplementation significantly reduced the risk of myocardial infarction in African Americans, while no such benefit was seen in non-Hispanic whites.
This suggests that genetic or lifestyle factors may influence the effectiveness of these supplements. Our findings highlight the importance of further research to better understand how race affects responses to omega-3 supplementation.
This suggests that genetic or lifestyle factors may influence the effectiveness of these supplements. Our findings highlight the importance of further research to better understand how race affects responses to omega-3 supplementation.
Read More
9
We explored the impact of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on heart disease through a significant study known as the VITAL trial. This study involved nearly 26,000 older adults in the U.S. and aimed to determine the effects of daily EPA supplementation on cardiovascular events over an average follow-up of 5.3 years.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Read More
User Reviews
USERS' SCORE
Good
Based on 19 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Improves heart rhythm
1 people found this helpful
These capsules are huge, which was surprising, but the taste is minimal. Since taking them, I've felt a marked improvement in my heart condition and rhythm.
Read More
9
No fishy taste
I appreciate the good price and concentration of this product. It’s halal and odourless, making it easy to consume, and it's effective for heart health.
Read More
9
Promotes heart health
NOW Foods Omega-3 provides 1000 mg per softgel with targeted EPA and DHA doses. It has an enteric coating that removes any fishy aftertaste, making it excellent for heart health and cognitive function.
Read More
9
High quality product
I trust the NOW brand. We’ve ordered various supplements from them and have always been satisfied. These Omega-3 fish oil supplements are beneficial, especially for joints and heart health.
Read More
9
Improves heart condition
1 people found this helpful
I have been purchasing this product for a long time. It’s high in omega-3 and good for heart health and hair. The taste is neutral, and it positively affects cholesterol levels, helping prevent inflammation.
Read More
Frequently Asked Questions
7.5
Improves heart rhythm
1 people found this helpful
These capsules are huge, which was surprising, but the taste is minimal. Since taking them, I've felt a marked improvement in my heart condition and rhythm.
9
Improves heart condition
1 people found this helpful
I have been purchasing this product for a long time. It’s high in omega-3 and good for heart health and hair. The taste is neutral, and it positively affects cholesterol levels, helping prevent inflammation.
7.5
Reduces cholesterol
I ordered this fish oil for the first time and found it beneficial for heart health and reducing cholesterol levels while also minimising inflammation in my body.
9
Beneficial for heart
It’s very good for heart health and cholesterol management; the packaging is just right.
9
Reduces inflammation
Omega 3 effectively lowers the risk of heart disease and arthritis by minimising inflammation. The capsule size is average, and the quality is excellent.
9
High quality product
I trust the NOW brand. We’ve ordered various supplements from them and have always been satisfied. These Omega-3 fish oil supplements are beneficial, especially for joints and heart health.
7.5
Mitigates heart disease
I use omega-3 with zinc, and I’ve noticed improvements in my hair and skin. My hair loss has decreased, and my cardiovascular health has benefited significantly.
7.5
Supports heart health
5 people found this helpful
Omega 3 is essential for reducing cholesterol and inflammation, which aids in preventing heart disease. It’s suitable for those who rarely consume fish, and the quality is excellent. The capsules have a mild fish taste, but the packaging is securely sealed.
9
We examined the relationship between plasma omega-3 levels and heart failure (HF), focusing on how this affects mortality in patients with existing HF. Our analysis of the UK Biobank, which included nearly 272,000 participants without HF, showed that higher omega-3 levels were linked to a 21% lower risk of developing HF over nearly 14 years.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
8
Omega-3 reduces heart disease risk
We explored the effectiveness of icosapent ethyl, a form of omega-3 fish oil, in lowering heart disease rates among high-risk patients with varying cholesterol levels.
In a clinical trial with statin-treated individuals who had elevated triglycerides, it was found that those taking icosapent ethyl experienced significantly fewer cardiovascular events compared to those on a placebo.
Notably, this benefit was seen regardless of their baseline low-density lipoprotein cholesterol (LDL-C) levels, indicating positive outcomes even for patients with well-controlled cholesterol.
In a clinical trial with statin-treated individuals who had elevated triglycerides, it was found that those taking icosapent ethyl experienced significantly fewer cardiovascular events compared to those on a placebo.
Notably, this benefit was seen regardless of their baseline low-density lipoprotein cholesterol (LDL-C) levels, indicating positive outcomes even for patients with well-controlled cholesterol.
8
Diet and fish oil improve heart health
We examined the effects of dietary changes, specifically through the MoKaRi study, to see how they influence heart health. Over 20 weeks, 65 participants followed personalized menu plans and received nutritional counselling.
The results were promising, showing notable reductions in various cardiometabolic risk factors. Adding fish oil supplements to these diets further enhanced the benefits, leading to better reductions in body weight, triglycerides, and blood sugar levels.
Overall, our findings suggest that combining a structured diet with fish oil can meaningfully improve heart health.
The results were promising, showing notable reductions in various cardiometabolic risk factors. Adding fish oil supplements to these diets further enhanced the benefits, leading to better reductions in body weight, triglycerides, and blood sugar levels.
Overall, our findings suggest that combining a structured diet with fish oil can meaningfully improve heart health.
8
We evaluated the impact of eicosapentaenoic acid (EPA) on heart disease, specifically focusing on its potential to reduce the risk of sudden cardiac death (SCD) and cardiovascular mortality (CVD mortality). Through a systematic review and meta-analysis, we gathered insights from 10 prospective cohort studies involving a total of 310,955 participants over an average follow-up period of 8.7 years.
Our analysis revealed that higher levels of omega-3 fatty acids, including EPA, in the blood were associated with a lower risk of both SCD and CVD mortality. Specifically, we found that individuals with high circulating levels of EPA and other omega-3s had a significantly reduced hazard ratio of 0.55 for SCD compared to those with lower levels. This suggests a protective effect linked to increased EPA intake.
Furthermore, our sub-analysis indicated that higher percentages of EPA and another omega-3 called DHA in the blood also correlated with a reduced risk of adverse cardiac events. These findings highlight the promising role of EPA as a beneficial component in cardiovascular health strategies.
Overall, the evidence suggests that increasing our intake of EPA could serve as an effective measure to lessen the incidence of serious heart-related issues, making it a topic worth considering in future dietary recommendations.
Our analysis revealed that higher levels of omega-3 fatty acids, including EPA, in the blood were associated with a lower risk of both SCD and CVD mortality. Specifically, we found that individuals with high circulating levels of EPA and other omega-3s had a significantly reduced hazard ratio of 0.55 for SCD compared to those with lower levels. This suggests a protective effect linked to increased EPA intake.
Furthermore, our sub-analysis indicated that higher percentages of EPA and another omega-3 called DHA in the blood also correlated with a reduced risk of adverse cardiac events. These findings highlight the promising role of EPA as a beneficial component in cardiovascular health strategies.
Overall, the evidence suggests that increasing our intake of EPA could serve as an effective measure to lessen the incidence of serious heart-related issues, making it a topic worth considering in future dietary recommendations.
9
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.
However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
8
We investigated how eicosapentaenoic acid (EPA) affects heart rhythm, particularly in the context of high-fat diets. In our study, mice were divided into two groups: one received a high-fat diet, while the other’s diet was supplemented with EPA for eight weeks.
We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
References
- Liepinsh E, Gukalova B, Krims-Davis K, Kuka J, Leduskrasta A, et al. EPA and DHA acylcarnitines are less cardiotoxic than are saturated and monounsaturated long-chain acylcarnitines. Biofactors. 2025;51:e70014. doi:10.1002/biof.70014
- Xu J, Peng T, Kong L, Wei N. A global analysis of the burden of ischemic heart disease attributable to diet low in ω-3 fatty acids between 1990 and 2021. BMC Cardiovasc Disord. 2025;25:188. doi:10.1186/s12872-025-04620-z
- Horii K, Ono K, Sumi T, Higashihara M, Zaima N, et al. Eicosapentaenoic acid prevents atrial electrocardiographic impairments and atrial fibrillation in high fat diet mice. J Physiol Sci. 2025;75:100014. doi:10.1016/j.jphyss.2025.100014
- Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, et al. Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study. Lipids Health Dis. 2025;24:88. doi:10.1186/s12944-025-02500-1
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Hemmati R, Bahrami Zanjanbar D, Shishesaz MI, Soleimani A, Yari T. The impact of Omega-3 supplementation on arrhythmia reduction in acute coronary syndrome patients: a randomized clinical trial. J Complement Integr Med. 2025;22:173. doi:10.1515/jcim-2024-0427
- Wang Y, Wu G, Wang Y, Rehman A, Yu L, et al. Recent developments, challenges, and prospects of dietary omega-3 PUFA-fortified foods: Focusing on their effects on cardiovascular diseases. Food Chem. 2025;470:142498. doi:10.1016/j.foodchem.2024.142498
- Jawad MA, O'Keefe JH, Tintle N, O'Keefe EL, Franco WG, et al. Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities. Mayo Clin Proc. 2024;99:1895. doi:10.1016/j.mayocp.2024.08.007
- Lee YQ, Tan KH, Chong MF. Biomarkers of PUFA and cardiovascular risk factors and events in healthy Asian populations: a systematic review. Br J Nutr. 2024;132:1474. doi:10.1017/S0007114524002708
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
- Ryuno Y, Kobayashi JI, Fujimoto Y, Dotare T, Matsue Y, et al. Effect of an Enteral Formula Enriched With ω-3 Fatty Acids, Carnitine, and Vitamin D on Body Weight, Heart Weight, and Blood Biochemical Parameters in a Dahl Rat Heart Failure Model. J Cardiovasc Pharmacol. 2024;84:590. doi:10.1097/FJC.0000000000001637
- Sun S, Hara A, Johnstone L, Hallmark B, Watkins JC, et al. Optimal Pair Matching Combined with Machine Learning Predicts a Significant Reduction in Myocardial Infarction Risk in African Americans Following Omega-3 Fatty Acid Supplementation. Nutrients. 2024;16. doi:10.3390/nu16172933
- Ahmadi M, Askari VR, Shahri B, Mousavi Noghab SM, Jarahi L, et al. Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:881. doi:10.1007/s00210-024-03330-1
- Chen HC, Tai CJ, Huang JY, Kuo TA, Huang YD, et al. Associations of fish oil with cardiovascular disease events: results from the Taiwan longitudinal study in aging. BMC Public Health. 2024;24:1979. doi:10.1186/s12889-024-19512-8
- Yu Y, Gao M, Xu H. Ginger Extract and Omega-3 Fatty Acids Supplementation: A Promising Strategy to Improve Diabetic Cardiomyopathy. Physiol Res. 2024;73:351.
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. doi:10.1007/s40261-024-01417-4
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
- Capece U, Gugliandolo S, Morciano C, Avolio A, Splendore A, et al. Erythrocyte Membrane Fluidity and Omega-3 Fatty Acid Intake: Current Outlook and Perspectives for a Novel, Nutritionally Modifiable Cardiovascular Risk Factor. Nutrients. 2024;16. doi:10.3390/nu16244318
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. doi:10.7759/cureus.73417
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
- Amangurbanova M, Daher R, Asbeutah AA, Vemuri B, Mirza H, et al. Higher epicardial adipose tissue volume is associated with higher coronary fatty plaque volume and is regulated by waist circumference but not EPA+DHA supplementation. J Clin Lipidol. 2024;18:e773. doi:10.1016/j.jacl.2024.06.006
- Kumakura H, Funada R, Matsuo Y, Iwasaki T, Nakashima K, et al. Eicosapentaenoic Acid Level Predicts Long-Term Survival and Cardiovascular or Limb Event in Peripheral Arterial Disease. Ann Vasc Dis. 2024;17:135. doi:10.3400/avd.oa.23-00079
- Xiao Y, Chen Y, Pietzner A, Elbelt U, Fan Z, et al. Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies. Nutrients. 2024;16. doi:10.3390/nu16111610
- Asbeutah AA, Daher R, Malik A, Hariri E, Alfaddagh A, et al. The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial. Am J Cardiol. 2024;225:98. doi:10.1016/j.amjcard.2024.06.001
- Sudo Y, Morimoto T, Tsushima R, Oka A, Sogo M, et al. Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation. J Am Heart Assoc. 2024;13:e033969. doi:10.1161/JAHA.123.033969
- Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024;150:425. doi:10.1161/CIRCULATIONAHA.123.065520
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. doi:10.1093/eurjpc/zwae315
- Lv L, Guo Y, Zheng Z, Li B. Blood metabolites mediate effects of breakfast skipping on heart failure via Mendelian randomization analysis. Sci Rep. 2024;14:18957. doi:10.1038/s41598-024-69874-7
- Wang Y, Yang B, Wang C. The association between fatty acids and atherosclerotic diseases: A mendelian randomization study. Clin Nutr ESPEN. 2024;63:447. doi:10.1016/j.clnesp.2024.06.018
- Tian S, Guo T, Qian F, Qiu Z, Lu Q, et al. Fish Oil, Plasma n-3 PUFAs, and Risk of Macro- and Microvascular Complications among Individuals with Type 2 Diabetes. J Clin Endocrinol Metab. 2024. doi:10.1210/clinem/dgae482
- Dinu M, Sofi F, Lotti S, Colombini B, Mattioli AV, et al. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. Eur J Prev Cardiol. 2024;31:1863. doi:10.1093/eurjpc/zwae184
- Braun TS, Drobner T, Kipp K, Kiehntopf M, Schlattmann P, et al. Validation of Nutritional Approaches to Modulate Cardiovascular and Diabetic Risk Factors in Patients with Hypertriglyceridemia or Prediabetes-The MoKaRi II Randomized Controlled Study. Nutrients. 2024;16. doi:10.3390/nu16091261
- O'Keefe EL, O'Keefe JH, Tintle NL, Westra J, Albuisson L, et al. Circulating Docosahexaenoic Acid and Risk of All-Cause and Cause-Specific Mortality. Mayo Clin Proc. 2024;99:534. doi:10.1016/j.mayocp.2023.11.026
- Zeinalabedini M, Ladaninezhad M, Mobarakeh KA, Hoshiar-Rad A, Shekari S, et al. Association of dietary fats with ischemic heart disease (IHD): a case-control study. J Health Popul Nutr. 2024;43:19. doi:10.1186/s41043-023-00489-w
- Rennemo J, Berge K, Yousaf MN, Eriksen TB, Welde E, et al. An Atypical Course of Cardiomyopathy Syndrome (CMS) in Farmed Atlantic Salmon () Fed a Clinical Nutrition Diet. Microorganisms. 2023;12. doi:10.3390/microorganisms12010026
